Testing a new drug for pancreatic cancer treatment
Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June 2019 as an amendment of the IND 137394)
This study is looking at a new drug called ABTL0812 to see if it can help people with pancreatic cancer by blocking certain pathways that cancer cells use to grow, and some patients will take it alone while others will take it with chemotherapy to find out how safe it is and if it can make their treatment better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10903737 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of ABTL0812, a novel drug that targets specific pathways involved in pancreatic cancer. The drug works by inhibiting the PI3K/Akt/mTOR pathway, which is crucial for cancer cell growth and survival. Patients will receive ABTL0812 either alone or in combination with chemotherapy to evaluate its safety and potential to improve treatment outcomes. The study aims to provide new therapeutic options for patients with pancreatic cancer, a condition with limited treatment success.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer who have not responded adequately to existing treatments.
Not a fit: Patients with early-stage pancreatic cancer or those who have not yet undergone any treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves survival rates and quality of life for patients with pancreatic cancer.
How similar studies have performed: Previous studies have shown promise in targeting the PI3K/Akt/mTOR pathway in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Sohal, Davendra — University of Cincinnati
- Study coordinator: Sohal, Davendra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.